Thank you, Mr. Chair.
Thank you, Ms. Vanni, for appearing before our committee. We're very grateful for the explanations you have provided.
I should say right off the bat that the results have been quite impressive. Since 2010, I understand that fatalities and mortality are down 47%, and we are the sixth biggest donor overall and the second biggest when it comes to tuberculosis, if I'm not mistaken. Most recently, there was a 16% increase in our replenishment, so thank you for all of the hard work you're doing.
I do understand, however, that, because of COVID, there has been a bit of a setback and you had to come up with a new strategy, a new strategy that incorporates greater considerations for equity, sustainability and innovation.
Even though I understand those terms in the abstract, I was wondering how that plays out on the ground insofar as introducing these programs is concerned.